Zynerba Pharmaceuticals Inc. (ZYNE) announced Tuesday morning that it has initiated its exploratory Phase 2 clinical trial of ZYN002 cannabidiol gel in children with Fragile X syndrome.
Zynerba Pharmaceuticals climbed throughout the second half of Tuesday’s session and closed up by 2.36 at $17.95 on above average volume. The stock broke out of a month and a half long trading range and set an 8 1/2 month high.
by RTT Staff Writer
For comments and feedback: email@example.com